Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Crovalimab Earns Approval in Europe for Paroxysmal Nocturnal Hemoglobinuria

August 27th 2024

The European Commission has approved crovalimab for adult and pediatric patients with paroxysmal nocturnal hemoglobinuria.

Amivantamab Plus Chemotherapy Wins EU Approval for Pretreated EGFR+ Advanced NSCLC

August 27th 2024

Amivantamab plus chemotherapy has received European approval for EGFR-mutant non–small cell lung cancer that progressed on an EGFR TKI.

Dr El-Jawahri on the Effects of Sexual Health Interventions in HSCT Recipients

August 26th 2024

Areej El-Jawahri, MD, discusses a trial investigating a multimodal intervention to enhance sexual function in patients who have previously received HSCT.

Dr Cecchini on Etrumadenant-Based Combinations in Previously Treated mCRC

August 26th 2024

Michael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.

Dr Saad on the Potential Predictive Value of IL7 SNPs in RCC

August 26th 2024

Eddy Saad, MD, MSc, the potential predictive value of IL-7 SNPs to inform treatment decisions for select patients with renal cell carcinoma.

DESTINY-Breast06 Redefines Treatment Paradigms, Calls Necessity of HER2 Testing for T-DXd into Question in HR+ Breast Cancer

August 26th 2024

Jason A. Mouabbi, MD, discusses shifting standards for HER2 testing for T-DXd administration and areas of ongoing ADC development within breast cancer.

DREAMM-7 and DREAMM-8 Data Support Belantamab Mafodotin–Based Combos in R/R Myeloma

August 24th 2024

Suzanne Trudel, MSc, MD, discusses updated data from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin–based regimens in R/R multiple myeloma.

Dr Linscott on the Need for Improved MRD Detection in High-Risk NMIBC

August 23rd 2024

Joshua Linscott, MD, PhD, discusses a study evaluating a utDNA assay for minimal residual disease detection in patients with high-risk NMIBC.

Dr Waks on Ongoing Research in Residual HER2+ Breast Cancer

August 23rd 2024

Adrienne G. Waks, MD, discusses efforts to improve treatment outcomes for patients with HER2-positive breast cancer with residual disease.

Weighing the Options: Considerations for Adjuvant CDK4/6 Inhibitor Selection in HR+ Breast Cancer

August 23rd 2024

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.

Dr Nanda on Treatment De-Escalation in HER2+ Breast Cancer and TNBC

August 22nd 2024

Rita Nanda, MD, discusses efforts to de-escalate adjuvant therapy for patients with select breast cancers who responded to neoadjuvant therapy.

Dr Hamilton on the Safety Profile of ADCs in HER2-Low and -Ultralow Breast Cancer

August 22nd 2024

Erika P. Hamilton, MD, discusses the safety profile of ADCs in patients with hormone receptor–positive, HER2-low and -ultralow breast cancer.

A New Wave of Endocrine Therapies Are Emerging in HR+ Breast Cancer

August 21st 2024

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.

Awareness Efforts Needed to Address Genetic Testing Disparities Among Male BRCA1/2 Carriers

August 20th 2024

Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.

Dr Braun on the Current Kidney Cancer Treatment Paradigm

August 16th 2024

David A. Braun, MD, PhD, discusses the variety of therapies available for the treatment of patients with kidney cancer.

Dr Miller on the Use of NK Cell Therapy in Hematologic Malignancies

August 16th 2024

Jeffrey S. Miller, MD, discusses research with natural killer cell therapy in patients with hematologic malignancies and other cancers.

Linvoseltamab Demonstrates Deep, Durable Responses in R/R Myeloma Ahead of FDA Action Date

August 15th 2024

Suzanne Lentzsch, MD, PhD, discusses updated data from the LINKER-MM1 study of linvoseltamab in relapsed/refractory multiple myeloma.

Ongoing Research Aims to Unveil the Optimal Use of Neoadjuvant and Adjuvant Therapies in TNBC

August 15th 2024

Linda T. Vahdat, MD, discusses investigations of ADCs and targeted agents in patients with TNBC and residual disease following chemoimmunotherapy.

Dr Oswalt on the Effects of Palliative Care Timing on End-of-Life Care in mNSCLC

August 15th 2024

Cameron James Oswalt MD, discusses a study evaluating the timing of palliative care referral and its effect on end-of-life care outcomes in mNSCLC.

Dr Kashima on T-Cell Phenotypes Associated With ICI Response/Resistance in RCC

August 15th 2024

Soki Kashima, MD, PhD, discusses a study investigating T-cell phenotypes associated with response or resistance to checkpoint inhibitors in RCC.